Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$12.3K Sell
92
-453
-83% -$51.3K ﹤0.01% 900
2026
Q1
$60.7K Buy
545
+453
+492% +$53.6K 0.01% 486
2025
Q4
$12.4K Buy
92
+17
+23% +$1.85K ﹤0.01% 810
2025
Q3
$6.37K Buy
+75
New +$4.6K ﹤0.01% 986

Other funds holding ABVX

LRI Investments's ABVX Position: Q2 2026 in Review

LRI Investments reduced its Abivax (ABVX) stake by 83% in Q2 2026, selling an estimated $51.3K and leaving 92 shares worth $12.3K. The position accounts for ﹤0.01% of the portfolio, ranked #900.

LRI Investments first reported a position in ABVX in Q3 2025 and has held it in 4 quarters since. The position peaked at $60.7K in Q1 2026. 303 funds tracked by Wall St. Rank hold ABVX as of Q2 2026.

  • LRI Investments held 92 shares of Abivax worth $12.3K as of Q2 2026.
  • LRI Investments sold 453 Abivax shares in Q2 2026, an estimated $51.3K.
  • Abivax made up ﹤0.01% of LRI Investments's portfolio in Q2 2026, its #900 holding.
  • LRI Investments first reported a position in Abivax in Q3 2025 and has held it in 4 quarters since.
  • LRI Investments's Abivax position peaked at $60.7K in Q1 2026.
  • 303 funds tracked by Wall St. Rank held Abivax as of Q2 2026.

Based on LRI Investments's 13F filing for Q2 2026, filed 14 Jul 2026.